Harbour BioMed announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences (SPRB). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences Secures $50 Million Term Loan Facility
- Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
- Spruce Biosciences initiated with an Outperform at Oppenheimer
- Two new option listings and eighteen option delistings on December 22nd
- Spruce Biosciences assumed with a Buy at H.C. Wainwright